Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Surgery Partners (SGRY) EBITDA (2016 - 2025)

Surgery Partners (SGRY) has disclosed EBITDA for 12 consecutive years, with $110.2 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 13.3% to $110.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $389.5 million through Dec 2025, up 11.67% year-over-year, with the annual reading at $559.7 million for FY2025, 13.39% up from the prior year.
  • EBITDA hit $110.2 million in Q4 2025 for Surgery Partners, up from $105.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $127.1 million in Q4 2024 to a low of $46.4 million in Q1 2023.
  • Historically, EBITDA has averaged $85.7 million across 5 years, with a median of $83.7 million in 2023.
  • Biggest five-year swings in EBITDA: skyrocketed 243.78% in 2021 and later crashed 53.78% in 2023.
  • Year by year, EBITDA stood at $114.8 million in 2021, then dropped by 17.94% to $94.2 million in 2022, then increased by 7.64% to $101.4 million in 2023, then grew by 25.35% to $127.1 million in 2024, then fell by 13.3% to $110.2 million in 2025.
  • Business Quant data shows EBITDA for SGRY at $110.2 million in Q4 2025, $105.7 million in Q3 2025, and $111.7 million in Q2 2025.